Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK). Panje CM, et al. Among authors: dedes kj. Radiother Oncol. 2018 Nov;129(2):257-263. doi: 10.1016/j.radonc.2018.07.017. Epub 2018 Aug 10. Radiother Oncol. 2018. PMID: 30104008 Clinical Trial.
Cost-effectiveness studies in ovarian cancer.
Szucs TD, Wyss P, Dedes KJ. Szucs TD, et al. Among authors: dedes kj. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:212-9. doi: 10.1111/j.1525-1438.2003.13355.x. Int J Gynecol Cancer. 2003. PMID: 14656283 Review.
Trastuzumab beyond progression: a cost-utility analysis.
Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Matter-Walstra KW, et al. Among authors: dedes kj. Ann Oncol. 2010 Nov;21(11):2161-2168. doi: 10.1093/annonc/mdq250. Epub 2010 May 5. Ann Oncol. 2010. PMID: 20444849 Free article.
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ. Matter-Walstra K, et al. Among authors: dedes kj. Breast Cancer Res Treat. 2016 Jul;158(1):51-57. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8. Breast Cancer Res Treat. 2016. PMID: 27277747
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
Matter-Walstra K, Schwenkglenks M, Dedes KJ. Matter-Walstra K, et al. Among authors: dedes kj. Breast Cancer Res Treat. 2017 Jun;163(3):635. doi: 10.1007/s10549-017-4209-5. Epub 2017 Mar 21. Breast Cancer Res Treat. 2017. PMID: 28321586 No abstract available.
97 results